+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
All Ages
All Genders
ID04580420

Phase 2 Open-Label Study of DCR-PHXC for Primary Hyperoxaluria Type 1 Patients with Severe Kidney Impairment, With or Without Dialysis

Led by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · Updated on 2025-12-24

28

Participants Needed

18

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating DCR-PHXC in individuals with Primary Hyperoxaluria Type 1 PH1 who have severe kidney impairment, including those on dialysis. This Phase 2 open-label study aims to assess the safety and effectiveness of DCR-PHXC in this specific patient group, which includes adults, children, and infants under 6 years old. The study is conducted by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, and focuses on participants with a confirmed PH1 diagnosis and significant kidney function decline. Participants will receive monthly subcutaneous injections of DCR-PHXC, with dosing schedules adjusted according to age and weight. After a screening period of up to 35 days, monthly dosing visits will continue through Day 180. Those completing the initial treatment phase may enter an extended follow-up period of up to five years or until the drug becomes commercially available. During this extension, dosing may be administered at home by participants, caregivers, or home health nurses with training. Throughout the study, participants will attend regular clinic visits for dosing and assessment. Researchers will monitor safety by tracking incidence of adverse events over 180 days. They will also evaluate changes in plasma oxalate levels, dialysis frequency and duration, and pharmacokinetics of DCR-PHXC. The total study duration can extend up to 10 years including the extended follow-up phase. Participants health and treatment compliance will be regularly assessed to understand the long-term effects of DCR-PHXC.

CONDITIONS

Brief Title

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

Research Team

N

Novo Nordisk

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here